Artificial intelligence and computational strategies are reshaping biotechnology with accelerated drug design and editing technologies. Insilico Medicine’s Chemistry42 AI platform identified novel pan-KRAS inhibitors with new chemotypes, overcoming challenges in targeting this oncogene. Meanwhile, a Yale University study enhanced multiplexed human gene editing with improved precision and efficiency, advancing the capabilities of CRISPR technologies. Additionally, Alphadesign, building upon AlphaFold’s protein structure prediction, facilitates de novo protein design binding specified targets. These innovations signal significant progress in AI’s ability to navigate complex biological spaces, expedite drug discovery, and expand genomic engineering.